IGIBvsXBI
iShares 5-10 Year Investment Grade Corporate Bond ETF against SPDR S&P Biotech ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| IGIB | XBI | |
|---|---|---|
| Expense ratio | 0.040% | 0.35% |
| Assets | $18.6B | $10.4B |
| Net flow, 1 month | +$479M | −$690M |
| Net flow, 1 year | +$3.5B | +$1.1B |
| Return, YTD | -6.7% | +26.7% |
| Return, 1 year | -7.1% | +52.4% |
| Avg daily volume | 3.6M | 8.6M |
| Holdings | 2744 | 135 |
| Listed | Jan 5, 2007 | Jan 31, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS